LCTX

Business Context and Reporting Period

Company: BioTime, Inc. (Note: Input metadata referenced Lineage Cell Therapeutics, but the filing text identifies BioTime, Inc.)
Reporting Period: Quarterly period ended September 30, 1997.
Status: Development stage company engaged in research and development of synthetic plasma expanders, blood volume substitutes, and organ preservation solutions. The company has not yet generated significant operating revenues and relies on equity financing and licensing fees.

Key Financial Metrics

Operating Expenses: Total expenses for the quarter were $1,183,766, comprised of $678,272 in Research & Development (R&D) and $505,494 in General & Administrative (G&A).
Interest Income: $76,145 for the quarter, driven by higher cash balances from a February 1997 offering.

Material Changes vs. Prior Period

• Revenue: Revenue of $125,000 was recognized from a license fee agreement with Abbott Laboratories. This contrasts with the prior year quarter where revenue was $187,500 (also license fees), though the current quarter's revenue is partially offset by deferred revenue recognition.
• Expenses: R&D expenses increased 57% to $678,272 from $432,166, driven by Phase III clinical trials for Hextend, data compilation, and bonus accruals. G&A expenses increased 65% to $505,494 from $306,353, primarily due to personnel costs and bonus accruals.
• Liquidity: Cash and cash equivalents decreased by $440,643 during the quarter to $7.37 million, despite a net loss of $982,621, due to $580,840 in net proceeds from the exercise of common share options and warrants.
• Stock Split: A three-for-one stock split was effected on October 30, 1997. All share data in the filing has been restated to reflect this split.

Guidance, Outlook, and Risks

Management Commentary & Outlook:

• Product Development: Phase III clinical trials for Hextend (blood plasma volume expander) are complete; data analysis is underway with results expected before the end of 1997. A clinical trial in London has also concluded.
• Licensing: An exclusive license agreement with Abbott Laboratories for Hextend in the U.S. and Canada provides for up to $40 million in license fees and royalties. $1.4 million has been received to date, with $1.212 million deferred. Future payments depend on regulatory milestones and sales.
• Capital Needs: Management expects to incur losses for the foreseeable future. Additional financing (equity or debt) may be required to complete clinical trials for new products (PentaLyte, HetaCool) and new indications for Hextend.

Risks and Contingencies:

• Regulatory Approval: Success depends on obtaining FDA and foreign regulatory approvals.
• Financing: Inability to secure additional financing could force the company to curtail or suspend operations.
• Market Competition: Competition from other companies developing similar products.
• Accounting Standards: The company must adopt SFAS 128 (Earnings Per Share) in the second quarter of fiscal 1998, which will require restating prior EPS data.

Investor Verification Checklist

• Cash Runway: Verify if the current cash balance of $7.37 million is sufficient to fund operations until the next expected milestone payment from Abbott or a new financing round.
• Deferred Revenue: Confirm the timeline for recognizing the $1.212 million in deferred revenue from the Abbott agreement.
• Clinical Trial Results: Monitor the release of Phase III Hextend trial data expected by the end of 1997, as this is critical for FDA approval and future revenue.
• Stock Dilution: Review the impact of the recent 3-for-1 stock split and outstanding options/warrants (651,000 shares available for future grants) on future share count.
• Abbott Milestones: Track the specific milestones required to trigger the remaining $1.1 million in near-term license payments from Abbott.